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Sean P. Roddy, MD, Philip S.K. Paty, MD, Kathleen J. Ozsvath, MD, and
R. Clement Darling III, MD, Albany, NY
Purpose: This study evaluated the outcomes of secondary procedures after endovascular aneurysm repair (EVAR).
Methods: From 2002 to 2009, 1768 patients underwent EVAR for treatment of 1662 elective (94%) and 106 emergent
(6%) infrarenal abdominal aortic aneurysm (AAA) with a variety of Food and Drug Administration-approved and
commercially available stent grafts. Postoperative follow-up included clinical examination, pulse volume recording,
duplex ultrasound imaging, and computed tomography andmagnetic resonance angiography at 1, 6, and 12months, and
yearly thereafter. Patients with type I and III endoleaks, unexplained endotension, limb occlusion, stent graft migration,
with and without type I endoleak, and aneurysm rupture underwent secondary interventions. Type II endoleak at >6
months without a decrease in the aneurysm sac underwent translumbar embolization. Data were prospectively collected.
Results: EVAR was performed in 1768 patients. During a mean follow-up of 34 (SD, 30.03) months, 339 patients
(19.2%) required additional secondary procedures for aneurysm-related complications, including type I (n 51, 15.0%),
type II (n 136, 40.1%), and type III (n 5, 1.5%) endoleaks; endotension (n 8, 2.4%), stent graft migration proximal
fixation site (n  46, 13.6%), stent graft iliac limb thrombosis or stenosis (n  25, 7.4%), subsequent iliac aneurysm
formation (n  39, 11.5%), or aneurysm rupture after EVAR (n  29, 8.6%). The mean age was 74 (SD, 9.15) years.
Mean AAA size was 5.7 (SD 3.24) cm. Compared with secondary procedures for AAA rupture, the nonrupture patients
had a significantly lower mortality (1.6% vs 17.2%, P < .05) and a higher likelihood of being managed by endovascular
means (98.8% vs 44.8%, P < .05). When nonruptured EVAR patients required urgent secondary procedures for type I
endoleaks and stent graft migration or limb thrombosis, the mortality was 6.0% vs 0.5% for elective procedures (P< .05).
Conclusions:Our long-term EVAR experience indicates that 18% of patients require additional secondary procedures, and
most of these patients can be managed by endovascular means with an acceptable overall mortality of 2.9%. Most type I
and II endoleaks can be successfully treated by transluminal embolization, and most patients with delayed aneurysm
rupture after EVAR can be successfully managed by endovascular or open surgical repair. ( J Vasc Surg 2010;52:1442-8.)Endovascular aneurysm repair (EVAR) is an acceptable
means for treating infrarenal abdominal aortic aneurysms
(AAA). However, complications of endoleaks, stent graft mi-
gration, stent fracture, aortic neck dilatation, or the develop-
ment of other aortoiliac aneurysms mandate lifelong patient
follow-up, and secondary interventions are required in ap-
proximately 15% to 20% of patients.1,2 Recent advances in
stent graft technology and improvement in vascular interven-
tionalists’ experience in performing these procedures has cer-
tainly led to routine use of EVAR in favorable as well as
unfavorable circumstances. The purpose of this current study
was to analyze our real-world experience with currently avail-
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1442able stent grafts in favorable and unfavorable conditions and
report on the outcomes of secondary interventions after
EVAR.
MATERIALS AND METHODS
From 2002 to 2009, 1768 patients underwent EVAR for
treatment of 1662 elective (94%) and 106 emergent (6%)
infrarenal AAA with a variety of U.S. Food and Drug Admin-
istration (FDA) approved and commercially available stent
grafts, including the Excluder (W. L. Gore and Assoc, Flag-
staff, Ariz), AneuRx (Medtronic, Santa Rosa, Calif), Zenith
(Cook, Bloomington, Ind), Talent (Medtronic), and End-
ologix (Irvine, Calif). The selection for a particular type of
stent graft with suprarenal or infrarenal fixation was at the
surgeon’s discretion. Postoperative follow-up included clini-
cal examination, pulse volume recording, duplex ultrasound
imaging, and computed tomography (CTA)/magnetic reso-
nance angiography (MRA) at 1, 6, and 12 months, and yearly
thereafter. The need for secondary procedures was defined on
the basis of postoperative complications that were confirmed
after EVAR, and included the following:
● All type I and III endoleakswere treated at the time of
diagnosis. Stent graft migration from the proximal fixa-
tion site was treated by placement of proximal extension
or conversion of the bifurcated stent grafts into aortou-
niiliac devices with advancement of a second stent graft
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When type I endoleaks develop in patients with CTA
demonstration of adequate stent graft opposition at the
aortic neck, a Palmaz stent (Cordis, Miami Lakes, Fla)
was placed at the juxtarenal aorta with partial overlap
within the stent graft main body and within the native
suprarenal aorta. In select patients, type I endoleaks were
also treated with translumbar coil embolization. All type
Ib endoleaks from a distal fixation site were treated by coil
embolization of the ipsilateral hypogastric artery and
stent graft extensions to the external iliac artery. Type III
endoleaks were treated with stent graft extensions at the
site of endoleak.
● Type II endoleaks with evidence of AAA sac growth or
a nonshrinking AAA sac 5.5 cm at 6 months after
EVAR underwent translumbar or transfemoral coil em-
bolization procedures. Our single-center experience in-
dicates that type II endoleaks are responsible for 15% to
20% of aneurysm ruptures after EVAR. Therefore, our
standard practice has been to treat type II endoleaks in
large (5.5 cm) nonshrinking AAA sacs.
● Endotension was considered to be a rule-out diagno-
sis when AAA sac increased in size 5 mm and no
obvious endoleak was identified. Treatment was indi-
vidualized based on the patient’s risk factors and in-
cluded stent graft relining using the low porosity Ex-
cluder stent graft, elective conversion to open surgical
repair, and in some instances, continued surveillance
without any further treatment.
● Stent graft migration from the proximal fixation site
and type I endoleak was treated with proximal stent graft
extensions up to the level of the lowermost renal artery.
For persistent type I endoleaks, a Palmaz stent was placed
at the aortic neck. Patients with stent graft migration
from the proximal fixation site without the presence of
type I endoleak underwent proximal stent graft extension
if the migration was 10 mm and the remaining stent
graft to aortic neck wall opposition was10 mm. None
of the patients with stent graft migration had surgical
conversion and stent graft explant as their initial treat-
ment.
● Symptomatic stent graft limb occlusion was prefer-
ably treated by a femoral artery cutdown and stent graft
limb thrombectomy. Our standard approach was to re-
line the thrombectomized iliac limb with a new iliac stent
graft limb as often there is some residual clot burden in
the iliac limbs, and findings of concomitant significant
external iliac artery stenosis were treated with a self-
expanding bare metal stent. A femoral-femoral crossover
bypass was reserved for instances when the patient had
chronic limb occlusion or attempted stent graft limb
thrombectomy was unsuccessful.
● Symptomatic stent graft limb stenosis was treated
by percutaneous placement of self-expanding or balloon-
expandable bare-metal stents at the site of critical
stenosis.
● Iliac aneurysm formation adjacent to iliac stent graft
limbs in patients with prior EVAR underwent treatmentif the iliac aneurysm maximum diameter was3 cm or if
failure of the stent graft seal at the distal fixation site
resulted in a type Ib endoleak. Patients underwent coil
embolization of the ipsilateral hypogastric artery with
stent graft extensions to the external iliac artery.
● AAA rupture after EVAR required secondary inter-
ventions that were endovascular or surgical, or both. The
approach was individualized and based primarily on the
patient’s anatomical suitability for EVAR at the time of
aneurysm rupture. Regardless of the patient’s hemody-
namic status, anatomically suitable patients with ruptured
AAA underwent an EVAR-first approach, and treatment
was tailored according to the cause of the stent graft
failure. The criteria to determine suitability for redo
EVAR were based on a detailed evaluation of the CTA,
which was used to identify the underlying etiology of
stent graft failure. The CTA findings were used to deter-
mine the feasibility of using proximal or distal extensions,
with or without Palmaz stent placement, and the under-
lying etiology for stent graft failure was treated. Aortic
occlusion balloons during the secondary or redo EVAR
were used as needed in hemodynamically unstable pa-
tients. When the ruptured AAA after EVAR was not
considered anatomically suitable for secondary or redo
EVAR, the patient underwent open surgical conversion
through a left retroperitoneal approach. In AAA rupture
patients with infrarenal stent grafts, aortic clamps were
generally placed at the suprarenal level, the aneurysm sac
was opened, the entire infrarenal stent graft was ex-
planted, including the iliac limbs, and aortoiliac recon-
struction was performed as needed. If the iliac limbs
could not be explanted due to scarring, the distal anasto-
mosis was constructed beyond the iliac stent grafts and
the aortic bifurcation over sewn, or the limbs were
transected at the aortic bifurcation and aortic tube grafts
were sutured directly to the distal aortic bifurcation.
Supraceliac aortic control was obtained in AAA rupture
patients with suprarenal stent grafts. Transaction of the
stent graft within the proximal aortic neck was primarily
considered in such cases, and the remainder of aortoiliac
reconstruction was performed as needed.
Data on primary EVAR as well as secondary and tertiary
interventions and their outcomes were prospectively col-
Table I. Secondary procedures after endovascular
aneurysm repair
Secondary procedures No. (%)
Total, No. 339
Type I endoleak 51 (15.0)
Type II endoleak 136 (40.1)
Type III endoleak 5 (1.5)
Endotension 8 (2.4)
Stent graft migration 46 (13.6)
Limb stenosis/thrombosis 25 (7.4)
Iliac aneurysm formation 39 (11.5)
Aneurysm rupture 29 (8.6)lected in a vascular registry and all variables were analyzed.
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From 2002 to 2009, 1768 patients underwent EVAR for
treatment of 1662 elective (94%) and 106 emergent (6%)
AAA. The mean age was 74 years (range, 49-97; SD, 9.15
years), the mean AAA size was 5.7 cm (range, 4.5-10.8; SD,
3.24 cm), and comorbidities included coronary artery disease
in 1291 (73.0%), hypertension in 1411 (79.8%), diabetes in
264 (14.9%), hypercholesterolemia in 834 (47.2%), chronic
obstructive pulmonary disease in 316 (17.9%), and end-stage
renal disease requiring dialysis in 152 (8.5%). During a mean
follow-up of 34 months (range, 1-96; SD, 30.03 months),
339 patients (19.2%) required additional procedures second-
ary to aneurysm-related complications. The etiology for these
339 secondary interventions included type I endoleaks in 51
(15.0%), type II endoleaks in 136 (40.1%), type III endoleaks
in 5 (1.5%), endotension in 8 (2.4%), stent graft migration
proximal fixation site in 46 (13.6%), stent graft iliac limb
thrombosis or stenosis in 25 (7.4%), subsequent iliac aneu-
rysm formation in 39 (11.5%), or aneurysm rupture after
EVAR in 29 (8.6%; Table I).
All secondary interventions and their outcomes are
listed in Table II. There was no statistically significant differ-
ence in the need for secondary interventions when elective and
emergent EVAR were compared. Nonfatal complications of
339 secondary interventions included myocardial infarction in
5 (1.5%), ischemic colitis requiring colostomy in 3 (0.9%),
renal failure requiring dialysis in 2 (0.6%), and wound infec-
tions in 7 (2.0%).
● Type I endoleaks with and without stent graft migra-
tion were treated in 51 of 339 patients (15.0%) by
proximal stent graft extensions in 19 (37.3%), trans-
lumbar coil embolization in 20 (39.2%), or open sur-
gical conversion with stent graft explants and aortoiliac
reconstruction in 5 (9.8%). Balloon-expandable
Palmaz stent placement at the aortic neck was required
in 14 patients (27.5%), and 8 patients (15.7%) with
Table II. Indications and outcomes of secondary procedu
Indication No. (%) S





Type II endoleaks 136 (40.1) Translum
Transfem
Type III endoleaks 5 (1.5) Stent gr
Endotension 8 (2.4) Stent gr
Stent graft migration 46 (13.6) Aortic st
Aortoun
Iliac stent graft limb thrombosis 25 (7.4) Stent gr
Femoral
Iliac aneurysms 39 (11.5) Iliac EV
AAA rupture 29 (8.6) Redo EV
Open su
CT, Computed tomography.type I endoleaks sealed spontaneously 1 month ofdiagnosis and did not require any further intervention.
At the time of their secondary interventions, seven
patients (14%) underwent Palmaz stent placement
along with proximal stent graft extensions in five (10%)
and coil embolization in two (4%). Two patients
(3.9%) died: an aortoenteric fistula developed in one
patient with translumbar coil embolization who died
of complications of the procedure, and one patient
with prior stent graft and a Palmaz stent died after
stent graft explant and aortoiliac reconstruction.
● Type II endoleaks were treated in 136 of 399 patients
(40.1%) by translumbar coil embolization in 124 (92%)
or transfemoral coil embolization in 12 (8%). One patient
(0.7%) died secondary to complications of stent graft and
aneurysm sac infection 6 months after the procedure.
● Type III endoleaks were treated in 5 of 339 patients
(1.5%) by stent graft extensions at the site of endoleak.
Four (80%) patients had displacement of stent graft-
stent graft overlap, and stent graft fabric tear was
presumed in one patient (20%). There were no major
complications or deaths.
● Stent graft migration from the proximal fixation site
was treated in 46 of 339 patients (13.6%), and 19
(41.3%) had associated type I endoleaks. Stent graft
migration from the proximal fixation site was treated
with stent graft extensions using aortic cuffs in 36
(78.3%). The Excluder stent graft main body was used
in 10 (21.7%) to convert bifurcated stent grafts into
aortouniiliac devices and a femoral-femoral bypass was
performed. One (2.2%) postoperative death occurred
secondary to cardiac complications.
● Iliac stent graft limb thrombosis or stenosis was
treated in 25 of 339 patients (7.4%) by stent graft
thrombectomy and relining with a new iliac stent graft
limb in 11 (44%) or femoral-femoral bypass in 14
(56%). One patient (4%) with complications of infec-
fter endovascular aneurysm (EVAR) repair
ary procedures No. (%) Mortality No. (%)
t graft extension 19 (37.3) 2 (3.9)
coil embolization 20 (39.2)
use at aortic neck 14 (27.5)
seal (CT/angiogram) 8 (15.7)
l conversion 5 (9.8)
coil embolization 124 (92) 1 (0.7)
coil embolization 12 (8)
tensions 5 (100) 0
lining 6 (75) 0
raft cuffs 36 (78.3) 1 (2.2)
conversion 10 (21.7)
rombectomy/relining 11 (44) 1 (4)
ral bypass 14 (56)
39 (100) 0
13 (44.8) 5 (17.2)

















rgication and multisystem organ failure died.
.6% (
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(11.5%) during a mean follow-up of 34 months and
required coil embolization of the hypogastric artery
and stent graft extension to the external iliac artery.
There were no major complications or deaths.
● Delayed AAA rupture after EVAR occurred in 29 of
339 patients (8.6%) during a mean follow-up of 29
months and was treated by redo-EVAR in 13 (44.8%)
or open surgical conversion in 16 (55.2%). The etiol-
ogy contributing to aneurysm rupture included type I
endoleak with stent graft migration in 19 patients
(65.5%), type II endoleaks in 6 patients (20.7%), and
undetermined etiology in 4 patients (13.8%). Redo
EVAR procedures were performed in 13 of 29 patients
(44.8%), and open surgical conversions with stent graft
explants and aortoiliac reconstructions were performed
in 16 patients (55.2%). Although the 30-day mortality of
redo EVAR was 7.8% vs 25% for surgical conversion, this
difference was not statistically significant.
● Repeat secondary procedures were required in an
additional 37 of 339 patients (10.9%) at a mean
follow-up of 8 months after the initial intervention.
These included translumbar coil embolization in 14
(37.8%) for treatment of type I endoleak in 3 (21.4%)
or type II endoleak in 11 (78.6%), proximal stent graft
extension for migration in 11 (29.7%), distal iliac stent
graft extensions in 5 (13.5%), and elective conversion
to open surgical repair in 7 (18.9%). There were no
major complications or deaths in this group. A com-
parison of mortality from secondary procedures after
EVAR indicates that, as expected, the outcomes in
nonruptured aneurysm patients is significantly better
than in ruptured AAA patients (17.2% vs 1.6%, P 
.05), and urgent secondary procedures have a higher
mortality compared with elective secondary proce-
dures (4.6% vs 0.4%, P .05) in patients with nonrup-
ture after EVAR (Table III). Furthermore, secondary
Table III. Mortality rate of secondary procedures after en
Secondary procedures after EV
For nonrupture F
Mortality 17.2% (5/29) 1.
U
4
Table IV. Endovascular vs surgical secondary intervention
Presentation Nonrupture after EV
Redo EVAR 98.8% (296/310)
Open surgical conversion 1.2% (14/310)
EVAR, Endovascular aneurysm repair.endovascular procedures were performed in a signifi-cantly higher number of patients with nonruptured
AAA after EVAR compared with patients with rupture
after EVAR (Table IV).
DISCUSSION
Our single-center real-world experience of treating elec-
tive and emergent AAA with favorable and unfavorable mor-
phology indicates that after the initial EVAR, the clinical
success at a mean of 34 months is 80.8% and the need for
secondary procedures is 19.2%. The factors influencing the
rate of secondary procedures include vigilance and duration of
patient follow-up and the decision for reintervention. In our
experience, the indication for secondary procedures from the
highest to the lowest frequency were type II endoleaks
(40.1%), type I endoleaks with stent graft migration (20.6%),
subsequent iliac aneurysm formation (11.5%), AAA rupture
after EVAR (8.6%), significant stent graft migration without
evidence of type I endoleak (8.0%), symptomatic iliac stent
graft limb stenosis or thrombosis (7.4%), endotension (2.4%),
and type III endoleaks (1.5%). These data provide several key
observations:
1. The mortality rate associated with these secondary pro-
cedures was significantly higher for AAA rupture after
EVAR (17.2%) than nonrupture (1.6%; P  .05).
2. When patients with nonruptured EVAR required ur-
gent secondary procedures such as treatment of type I
and III endoleaks, stent graft migration, and iliac limb
thrombosis, the mortality (4.6%) was significantly
higher than for elective procedures such as treatment of
type II endoleaks and endotension (0.4%; P  .05).
3. A significantly higher percentage of patients requiring
secondary interventions for nonruptured AAA after
EVAR can be managed by endovascular means com-
pared with patients who present with rupture after
EVAR (98.8% vs 44.8%, P  .001; Tables III and IV).
When secondary interventions are required for EVAR
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ARfailure, there are a variety of reasons and means of treatment
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local expertise in dealing with the stent graft failures.3,4
Initially in our experience, when we treated type I endoleaks,
we performed the standard and justified procedures of proxi-
mal stent graft extensions with and without the use of Palmaz
stents at the aortic neck. Patients with persistent type I en-
doleak regardless of proximal extensions and Palmaz stent that
were at high risk for open surgical conversion underwent
translumbar arteriogram and embolization for treatment of
type I endoleak. This procedure was successful in eliminating
type I endoleak in 70% (14 of 20) of patients. The technique
for this translumbar procedure is similar to that when treating
type II endoleaks: once in the aneurysm sac the catheter is
directed toward the endoleak channel at the aortic neck and
coils are packed densely at the endoleak track.
None would argue the benign nature of type II endoleak
in face of an AAA sac that has decreased in size after EVAR.
However, there has been an increasing recognition during the
past several years of increased adverse events in patients with
type II endoleaks and nonshrinking as well as enlarging AAA
sacs.5 Although earlier European Collaborators on Stent-
Graft Techniques for Aortic Aneurysm Repair (EUROSTAR)
data suggested all type II endoleaks were benign, more recent
publications have reported that patients with type II endoleaks
have an increased composite adverse event rate of 55% com-
pared with 15% for those without type II endoleaks (P 
.05).6 In treating AAA with type II endoleaks with sac growth
and stable sac size of 5.5 cm at 6 months, we have
routinely adopted the translumbar embolization technique
and found this was successful in eliminating the type II en-
doleak in two-thirds of the patients; the transfemoral approach
is generally reserved for translumbar failures. Historically, on
the basis of earlier data, some would argue that type II en-
doleaks without enlarging AAA sacs should be left untreated,
and if one were to adopt that approach, the overall incidence
of secondary procedures after EVAR would be considerably
less than ours at 19.2%, because 40% of our patients had
secondary interventions for type II endoleaks. We cannot
provide further information on type II endoleaks with and
without enlarging AAA sacs, which is a limitation of this data
set.
Type III endoleaks are fairly infrequent events and should
be treated when diagnosed. The most common methods
include stent grafts extensions, mostly iliac stent graft limbs, at
the site of stent graft separation. Rarely, stent graft component
separation results in the need for conversion of bifurcated
stent grafts into aortouniiliac devices or open surgical conver-
sion. Endotension is considered to be a rule-out diagnosis,
and is usually made when CTA, duplex ultrasound imaging,
and arteriography fail to indicate any endoleaks in the presence
of an enlarging AAA sac. To some extent, all currently avail-
able devices have various porosities that can contribute to
AAA sac growth without evidence of endoleak, and treatment
should be individualized according to the patient’s risk factors
for various procedures. When porosity is suspected to be the
culprit of AAA sac growth without evidence of any endoleaks,
stent graft relining has been shown to be of value in halting sac
growth.7,8The standard accepted treatment for stent graft migration
associated with type I endoleak involves securing the seal at
the aortic neck with stent graft extensions, as needed. The type
of proximal stent graft extension depends on the aortoiliac
morphology, the etiology for stent graft migration, and the
relationship between the stent graft and the aortic neck, and it
is for these reasons that conversion of bifurcated stent grafts
into aortouniiliac devices and femoral-femoral bypass are
sometimes needed.9
Treatment of stent graft migration without an identifiable
type I endoleak remains controversial. We reserved treatment
of stent graft migration without type I endoleak when several
criteria were met, including (1) when stent graft migration
was noted in patients with complex aortic necks, and (2) the
stent graft migration was 10 mm, and (3) the remaining
stent graft to aortic neck wall opposition was 10 mm, in
AAA 5 cm. In our experience, 59% of patients with signifi-
cant stent graft migration did not have an identifiable type I
endoleak, and all underwent successful proximal extensions
without any notable morbidity and mortality; this would
account for 1.5% (27 of 1768) of all EVAR patients.
Secondary procedures for iliac limb thrombosis ac-
counted for 1.4% (25 of 1768) of all EVAR patients, and 44%
of these patients who underwent successful redo EVAR pro-
cedures with the stent graft iliac limb underwent thrombec-
tomy. We routinely relined with a new iliac stent graft limb,
although it is not clear if that would be an absolute necessity.
After thrombectomy, when stent graft limbs are noted to have
strictures/kinks, or when the outflow has identifiable stenosis,
based on our experience we would recommend treatment
directed toward the potential underlying etiology for stent
graft thrombosis. Of the 25 patients who underwent treat-
ment for iliac stent graft limb thrombosis, one death occurred
secondary to postoperative myocardial infarction. One can use
stent grafts, bare metal balloon-expandable, or self-expanding
stents to treat these lesions, although data evaluating these
procedures are lacking.
The fundamental goal of AAA repair by surgical or endo-
vascular means is to reduce the risks for aneurysm rupture and
death. However, none of the currently available devices are
completely effective in preventing aneurysm rupture after
EVAR, and lifelong surveillance of these stent grafts and
aneurysms is needed. In our experience, patients presenting
with aneurysm rupture after EVAR tend not to exhibit pro-
found signs of hemodynamic collapse, and their symptoms are
generally that of abdominal and back pain. As long as the
patients maintain a measurable blood pressure, the techniques
of hypotensive hemostasis by limiting the resuscitation to
maintain a detectable blood pressure can help minimize on-
going hemorrhage. Detailed evaluation of the CTA to identify
the etiology of stent graft failure and aneurysm rupture is vital
for planning for redo EVAR. The placement of the stent graft
extensions—proximal, distal, or within the stent graft compo-
nents to achieve stent graft fixation and seal and treat the
ruptured aneurysm—is done on the basis of the CTA and
intraoperative arteriogram findings, and endovascular therapy
is targeted toward the underlying etiology for stent graft
failure.
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uting to aneurysm rupture after EVAR included type I en-
doleak (65%). What was unexpected was that type II en-
doleaks were the only notable findings and were considered
responsible for 21% of AAA ruptures after EVAR, and in 14%
of patients, the etiology for AAA rupture was undetermined.
Redo EVAR procedures were performed in 13 of 29 patients
(44.8%), and open surgical conversions with stent graft ex-
plants and aortoiliac reconstructions were performed in 16
patients (55.2%). The 7.8% mortality rate for the redo EVAR
group was better than the 25% rate in the open surgical
conversion group, although this difference was not statistically
significant. Delayed AAA rupture after EVAR can be success-
fully managed in most patients by open surgical conversion or
redo EVAR. The approach to each patient should be individ-
ualized. Complete stent graft explant is not necessary in most
patients, and a secondary EVAR for delayed AAA rupture,
with or without an elective conversion to open surgical repair,
remains an option. In 29 patients that presented with aneu-
rysm rupture, the overall mortality was 17.2%, and all 5 patient
deaths were secondary to cardiovascular collapse and multior-
gan system failure.
We preferentially use the retroperitoneal approach for
treatment of ruptured AAA in patients requiring open surgical
conversion, and this also has been our standard approach for
managing AAA rupture after EVAR. If the etiology of the
aneurysm rupture is secondary to type I, II, or III endoleak
and can be determined by a preoperative CT scan, the surgeon
may have some foresight into the further options for subse-
quent revascularization. Often the etiology of the aneurysm
sac rupture is only determined after the aortic sac is opened.
Kelso et al10 reported their experience of 41 stent graft ex-
plants after EVAR and found the mortality was significantly
higher for ruptured vs nonruptured aneurysms (66% vs 9%).10
Our single-center experience at The Vascular Institute for
Health and Disease in Albany is the largest contemporary
series to date that analyzes the outcomes of real-world expe-
riences with EVAR using currently available third- and fourth-
generation stent grafts. Our findings remain consistent with
several other reports highlighting the need for repeat interven-
tions after EVAR and the need for lifelong surveillance after
EVAR. Our purpose was to analyze the real-world EVAR
experience. Stent graft technology has undergone significant
evolution in the past decade, with changing indications for use
per device. Unfortunately, we did not have the data on indi-
cations for use for each device, and therefore, we did not
analyze the percentage of failures by device but, rather, fo-
cused on the outcomes of secondary interventions after EVAR
when needed, regardless of the device type:
● Abbruzzsese et al11 evaluated their experience of device-
specific long-term outcomes of 565 elective EVAR pa-
tients treated during a 7-year period ending in 2005.
Their findings indicated that although the reinter-
vention rate was comparable among various FDA-
approved devices, stent graft application outside the
indications for use had a negative effect on late results.● Pitoulias et al12 reported 625 elective EVAR, indicat-
ing that 16.2% of patients required secondary proce-
dures during a mean follow-up of 47 months; the
mortality rate of their patients undergoing emergent
secondary procedures was substantially higher than
that of elective procedures (8.8% vs 20%).
● Verhoeven et al13 reported similar findings of 308
EVAR patients, indicating a reintervention rate of
15%; two-thirds were elective and one-third emergent,
with 80% of the patients undergoing a successful en-
dovascular secondary intervention and the overall
open surgical conversion rate of 3%.
● Becquemin et al14 evaluated their 8-year experience of
250 EVAR patients and reported a secondary interven-
tion rate of 27% at a mean follow-up of 19 months and
had similar findings indicating that the secondary inter-
ventions did not lead to increased mortality, rather more
surgical conversions and a higher clinical failure rate.
CONCLUSIONS
Our long-term experience indicates that approximately
19% of patients require additional second and third proce-
dures, and almost all of these patients can be managed by
endovascular means with acceptable overall morbidity and
mortality. Translumbar coil embolization can be used as an
adjunctive procedure for treating type I endoleaks. Most
patients with delayed aneurysm rupture after EVAR can be
successfully managed by endovascular or open surgical repair
with comparable mortality. Aggressive management of late
complications may minimize the mortality associated with this
procedure.
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Dr Marc A. Passman (Birmingham, Ala). I would like to
congratulate Dr Mehta and his colleagues from Albany, New
York, on an excellent paper, and applaud the program commit-
tee for inviting some cross-regional work onto our Southern
Association for Vascular Surgery (SAVS) program. Over an
8-year experience, the group from Albany performed 1768
endovascular abdominal aortic aneurysm (AAA) repairs, of
which 19.2%, or almost 1 in 5, required some secondary or
tertiary procedure. Interestingly, we just reviewed our endovas-
cular experience at University of Alabama at Birmingham
(UAB), which will be presented at another vascular meeting
later this year. Over a similar time period representing about
1100 stent graft repairs, in our experience only 9.2%, or 1 in 10,
required a secondary procedure, a rate less than half of what was
presented here. I will try to avoid the tempting regional com-
parison that perhaps we know how to do endovascular AAA
repairs more definitively in our Southern region compared with
the great state of New York. Rather, there are likely some
differences in our respective experiences that form the focus of
my questions.
First, you state in the manuscript that stent grafts were per-
formed in both “favorable and unfavorable” conditions, but no
further definition or analysis is provided. Assuming what you term
“unfavorable conditions” relates to more anatomically challenging
situations, were you able to stratify your data set of secondary
procedures within the larger overall endovascular aneurysm repair
population to determine if use in “unfavorable conditions” was a
predictor for stent graft failure and the need for secondary proce-
dure?
Second, because 40% of your secondary procedure needs were
for type II endoleak, much of your data analysis is driven by this
dominant subgroup. Perhaps the overall larger need for secondary
procedures in your study is in part reflective of a more aggressive
approach for type II endoleaks. What percentage of the larger
overall endovascular aneurysm repair population had type II en-
doleaks, and what percentage of these type II endoleaks required a
secondary procedure? Please clarify what criteria are used to inter-
vene for a type II endoleak within your group and if indeed your
approach is more aggressive.
Third, with such a large group of vascular surgeons within the
Albany practice, was there some degree of surgical variability or
perhaps surgeon outliers that accounted for a larger portion of
failed primary endovascular stent graft repairs or need for second-
ary procedures?
Fourth and finally, with such a large reported experience over
an extended time period, there is an opportunity here to look at
time-dependent data. Have you had a chance to look at anysecondary procedures may arise and what type of secondary proce-
dure was required at that time point?
Again, all regional considerations aside, I wish to welcome the
group from Albany to our meeting and appreciate the opportunity
to discuss this paper.
DrManish Mehta. On behalf of The Albany Vascular Group
I would like to thank the Southern Association of Vascular Surgery
for extending us an invitation. Furthermore I would like to thank
Dr Passman for discussing this paper. Marc, I appreciate your
insightful questions and comments. Your question whether we can
predict stent graft failures based on favorable versus unfavorable
conditions is a good one, and currently available data would
suggest that when we treat patients that meet the IFUs for a
particular stent graft, the outcomes tend to be better than patients
that fall outside the IFUs, ie short necks, short/angulated necks,
etc. I can tell you that less than 50% of our aneurysm patient
population would meet the IFUs to be enrolled in currently
ongoing stent graft trials, and would be considered to have favor-
able anatomy.
Unfortunately we did not quantify morphological variables
that would allow us to analyze IFUs per stent graft and match them
to anatomically favorable versus unfavorable characteristics in our
patient population. The goal of our study was to analyze the
outcomes of secondary procedures following endovascular aneu-
rysm repair. Treatment of type 2 endoleaks remains a controversial
issue. At Albany, we have reserved treating type 2 endoleaks in
patients with aneurysm sac size increase of greater than 5mm
following EVAR, and in large abdominal aortic aneurysms greater
than 5.5cm with persistent type 2 endoleaks at greater than 6
months after EVAR. This is a reflection of our experience discov-
ering that up to 20% of aneurysm ruptures following EVAR are
secondary to type 2 endoleaks. Furthermore, there have been
several recent papers suggesting that patient with persistent type 2
endoleaks tend to have worse outcomes over long term follow up.
The translumbar approach for embolization of these endoleaks is a
relatively benign procedure, and so we have considered this as a
viable option in select patients.
To answer your question regarding the surgical variability of a
large number of vascular surgeons in Albany, as you know we have
17 vascular surgeons, but as you also know, we pride ourselves in
developing structured standardized approaches to all procedures
whether they are distal bypass, carotid endarterectomy, or endo-
vascular repair. I think that overall we did not analyze the surgical
variability amongst different partners, and the need for secondary
procedures following EVAR, but my sense would be that there
really would not be much of a difference since we all perform these
procedures in a very similar manner.
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that as we got more experienced, patients would need less
secondary interventions. What I think is happening is that with
gaining significant experience, we are also treating more com-
plex aortoiliac aneurysms by endovascular means, and thislowing EVAR might not change with increasing experience.
The important point that we have learned here is that the risks of
secondary interventions are little under controlled elective cir-
cumstances, when compared to emergent circumstances, so
vigilant patient follow up remains a vital component of endo-would mean that the incidence of secondary interventions fol- vascular aneurysm therapy.
